Cerebrolysin Research Protocols & Administration Dosing in Published Research Research investigations have employed diverse Cerebrolysin doses depending on species, condition, and route: Preclinical Studies: Rat stroke models: 2.5-7.5 ml/kg optimal range (0.8-7.5 ml/kg studied) Rat TBI models: 2.5 ml/kg identified as optimal dose Mouse neurodegenerative models: 5 ml/kg typical dose Administration timing: Usually 4 hours post-injury, daily for 10-21 days Human Clinical Trials: Acute stroke: 30-50 ml/day intravenously for 10-21 days Vascular dementia: 20-30 ml/day for 4-week cycles Alzheimers disease: 10-60 ml/day for 4-24 weeks Traumatic brain injury: 30-50 ml/day for 10-21 days Important: These dosing regimens are specific to the conditions and species studied and cannot be extrapolated across species or indications due to significant differences in pharmacokinetics, peptide metabolism, receptor expression patterns, and disease pathophysiology
Peptide reduces inflammation in the eye Conducted by a team of veterinary researchers, the study explores the use of a SOCS1-KIR mimetic peptide in an eyedrop formulation
Brcic, Luka
Subsequently, animals were placed at the end of one arm and allowed to explore freely among the three arms of the Y-maze for 8 minutes
This test, which evaluates depressive states through the analysis of immobility and struggle times, demonstrated that the control group displayed minimal depressive-like behaviors, as evidenced by the lowest percentage of immobility
